Trials / Active Not Recruiting
Active Not RecruitingNCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acalabrutinib | Participants will receive acalabrutinib as stated in the arms' description. |
Timeline
- Start date
- 2014-01-30
- Primary completion
- 2021-07-15
- Completion
- 2027-06-09
- First posted
- 2014-01-08
- Last updated
- 2026-02-06
- Results posted
- 2022-09-10
Locations
12 sites across 3 countries: United States, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT02029443. Inclusion in this directory is not an endorsement.